The understanding of Epstein-Barr virus associated lymphoproliferative disorder
In recent years, there are increasing articles concerning Epstein-Barr virus associated lymphoproliferative disorder (EBV+ LPD), and the name of EBV+ LPD is used widely. However, the meaning of EBV+ LPD used is not the same, which triggered confusion of the understanding and obstacles of the communication. In order to solve this problem. Literature was reviewed with combination of our cases to clarify the concept of EBV+ LPD and to expound our understanding about it. In general, it is currently accepted that EBV+ LPD refers to a spectrum of lymphoid tissue diseases with EBV infection, including hyperplasia, borderline lesions, and neoplastic diseases. According to this concept, EBV+ LPD should not include infectious mononucleosis (IM) and severe acute EBV infection (EBV+ hemophagocytic lymphohistiocytosis, fatal IM, fulminant IM, fulminant T-cell LPD), and should not include the explicitly named EBV+ lymphomas (such as extranodal NK/T cell lymphoma, aggressive NK cell leukemia, Burkitt lymphoma, and Hodgkin lymphoma, etc.) either. EBV+ LPD should currently include: (1) EBV+ B cell-LPD: lymphomatoid granulomatosis, EBV + immunodeficiency related LPD, chronic active EBV infection-B cell type, senile EBV+ LPD, etc. (2) EBV+ T/NK cell-LPD: CAEBV-T/NK cell type, hydroa vacciniforme, hypersensitivity of mosquito bite, etc. In addition, EBV+ LPD is classified, based on the disease process, pathological and molecular data, as 3 grades: grade1, hyperplasia (polymorphic lesions with polyclonal cells); grade 2, borderline (polymorphic lesions with clonality); grade 3, neoplasm (monomorphic lesions with clonality). There are overlaps between EBV+ LPD and typical hyperplasia, as well as EBV+ LPD and typical lymphomas. However, the most important tasks are clinical vigilance, early identification of potential severe complications, and treating the patients in a timely manner to avoid serious complications, as well as the active treatment to save lives when the complications happened.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Zhonghua bing li xue za zhi = Chinese journal of pathology - 45(2016), 12 vom: 08. Dez., Seite 817-821 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Zhou, X G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.07.2017 Date Revised 31.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.issn.0529-5807.2016.12.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM267711972 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM267711972 | ||
| 003 | DE-627 | ||
| 005 | 20231224221300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.issn.0529-5807.2016.12.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0892.xml |
| 035 | |a (DE-627)NLM267711972 | ||
| 035 | |a (NLM)28056294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Zhou, X G |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The understanding of Epstein-Barr virus associated lymphoproliferative disorder |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2017 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In recent years, there are increasing articles concerning Epstein-Barr virus associated lymphoproliferative disorder (EBV+ LPD), and the name of EBV+ LPD is used widely. However, the meaning of EBV+ LPD used is not the same, which triggered confusion of the understanding and obstacles of the communication. In order to solve this problem. Literature was reviewed with combination of our cases to clarify the concept of EBV+ LPD and to expound our understanding about it. In general, it is currently accepted that EBV+ LPD refers to a spectrum of lymphoid tissue diseases with EBV infection, including hyperplasia, borderline lesions, and neoplastic diseases. According to this concept, EBV+ LPD should not include infectious mononucleosis (IM) and severe acute EBV infection (EBV+ hemophagocytic lymphohistiocytosis, fatal IM, fulminant IM, fulminant T-cell LPD), and should not include the explicitly named EBV+ lymphomas (such as extranodal NK/T cell lymphoma, aggressive NK cell leukemia, Burkitt lymphoma, and Hodgkin lymphoma, etc.) either. EBV+ LPD should currently include: (1) EBV+ B cell-LPD: lymphomatoid granulomatosis, EBV + immunodeficiency related LPD, chronic active EBV infection-B cell type, senile EBV+ LPD, etc. (2) EBV+ T/NK cell-LPD: CAEBV-T/NK cell type, hydroa vacciniforme, hypersensitivity of mosquito bite, etc. In addition, EBV+ LPD is classified, based on the disease process, pathological and molecular data, as 3 grades: grade1, hyperplasia (polymorphic lesions with polyclonal cells); grade 2, borderline (polymorphic lesions with clonality); grade 3, neoplasm (monomorphic lesions with clonality). There are overlaps between EBV+ LPD and typical hyperplasia, as well as EBV+ LPD and typical lymphomas. However, the most important tasks are clinical vigilance, early identification of potential severe complications, and treating the patients in a timely manner to avoid serious complications, as well as the active treatment to save lives when the complications happened | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Zhang, Y L |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Y Y |e verfasserin |4 aut | |
| 700 | 1 | |a Li, W S |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, H |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, F |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, H X |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, P |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Z |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Y C |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, H L |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, W H |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, G |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, X C |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, G |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, G |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, S F |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, J |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Y Q |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, W J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua bing li xue za zhi = Chinese journal of pathology |d 1985 |g 45(2016), 12 vom: 08. Dez., Seite 817-821 |w (DE-627)NLM012624403 |x 0529-5807 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2016 |g number:12 |g day:08 |g month:12 |g pages:817-821 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2016.12.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2016 |e 12 |b 08 |c 12 |h 817-821 | ||